ALK increases sales in Q2, but operating result decreases
Wednesday morning, allergy company ALK presented the full report for the year's second quarter. The central figures were known ahead of time, since the company upgraded its guidance on Monday.
BY ALBERT RØNNING-ANDERSSON, TRANSLATED BY NIELSINE NIELSEN
Wednesday morning, pharmaceutical company ALK shed light on the last unknown figures in the company's Q2 report. Since the firm published the main figures for the quarter on Monday, there were no great surprises.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
ALK upgrades guidance following convincing sales and savings
For subscribers
ALK nominates former Sanofi executive for board membership
For subscribers
.jpg&w=384&q=75)
